Edgardo Santiago-Guzman, MD
Hematology & Oncology · San Juan, PRNPI 1487938031
Payments from drug & device makers
Across 1,013 payments — averaging $78.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$55K
- AbbVie$8K
- Merck$3K
- AstraZeneca$2K
- PBG Puerto Rico LLC$2K
- Genentech USA, Inc.$1K
- plus $8K from 35 others
What the payments were for
- Consulting fees$18,38423%
- Speaking & faculty fees$35,39645%
- Travel & lodging$3,6875%
- Food & beverage$21,14827%
- Education$4961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 281 | $54,507 |
| AbbVie | 70 | $8,467 |
| Merck | 93 | $2,968 |
| AstraZeneca | 87 | $1,885 |
| PBG Puerto Rico LLC | 77 | $1,575 |
| Genentech USA, Inc. | 61 | $1,275 |
| Bristol Myers Squibb | 6 | $1,022 |
| Johnson & Johnson(2 entities) | 42 | $900 |
| Novartis | 36 | $826 |
| Eli Lilly Export S.A. Puerto Rico Branch | 29 | $609 |
| Amgen | 38 | $609 |
| Bayer Puerto Rico Inc. | 24 | $598 |
| Bayer | 21 | $464 |
| GSK | 16 | $387 |
| Sanofi | 17 | $347 |
| Exelixis Inc. | 15 | $327 |
| Tempus AI, Inc | 13 | $304 |
| Eisai Inc. | 16 | $287 |
| Incyte Corporation | 9 | $233 |
| Taiho Oncology, Inc. | 9 | $182 |
| Puma Biotechnology, Inc. | 9 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $161 |
| Karyopharm Therapeutics Inc. | 1 | $124 |
| Genentech, Inc. | 1 | $124 |
| Seagen Inc. | 3 | $114 |
| Pfizer Pharmaceuticals LLC | 6 | $97 |
| Lilly USA, LLC | 4 | $85 |
| Sobi, Inc | 4 | $84 |
| Morphosys, US Inc. | 2 | $50 |
| Pfizer | 4 | $48 |
| Mirati Therapeutics, Inc. | 2 | $45 |
| Beigene USA, Inc. | 2 | $42 |
| Caris MPI, Inc. | 2 | $37 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Genmab U.S., Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,111 in reported general payments places this provider in the 80th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 22 | $351,780 |
| LenvimaLenvatinib Mesylate | 12 | $295,835 |
| NubeqaDarolutamide | 21 | $266,349 |
| VerzenioAbemaciclib | 13 | $232,665 |
| TagrissoOsimertinib Mesylate | 13 | $215,191 |
| VenclextaVenetoclax | 11 | $149,878 |
| PromactaEltrombopag Olamine | 14 | $130,343 |
| Somatuline DepotLanreotide Acetate | 13 | $121,820 |
| Abiraterone Acetate | 50 | $119,874 |
| AvastinBevacizumab | 11 | $63,755 |
| RetacritEpoetin Alfa-Epbx | 26 | $33,825 |
| EliquisApixaban | 38 | $26,102 |
| XareltoRivaroxaban | 31 | $21,817 |
| Sucralfate | 25 | $9,881 |
| Anastrozole | 357 | $6,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Retacrit, Eliquis | $48 | $411,70786 claims |
| Eisai Inc.Lenvima | $287 | $295,83512 claims |
| BayerNubeqa | $464 | $266,34921 claims |
| Lilly USA, LLCVerzenio | $85 | $232,66513 claims |
| AstraZenecaTagrisso | $1,885 | $215,19113 claims |
| AbbVieVenclexta, Synthroid | $8,467 | $152,17643 claims |
| NovartisPromacta | $826 | $130,34314 claims |
| Genentech, Inc.Avastin | $124 | $63,75511 claims |
| Johnson & JohnsonXarelto | $900 | $21,81731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in San Juan
- Mirelis AcostaSan Juan$6.3M
- Luis FloresSan Juan$2.3M
- Noridza Rivera RodriguezSan Juan$2.1M
- Adelba Torres-LopezSan Juan$1.9M
- Jose Lozada CostasSan Juan$934K
- Fernando CabanillasSan Juan$916K
- Alexis Cruz ChaconSan Juan$505K
- Luis Baez VallecilloSan Juan$350K
- Cristian Rodriguez ArochoSan Juan$227K
- Josselyn Molina AvilaSan Juan$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.